Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0054
Source ID: NCT00338000
Associated Drug: Epoetin Alfa
Title: EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Chronic Renal Failure
Interventions: DRUG: Epoetin alfa
Outcome Measures: Primary: Hemoglobin change - reach of target Hb levels (measured at Visit 1, 2, 3, 4) | Secondary: Prevention of left ventricular hypertrophy (measured at Visit 3 and 4)
Sponsor/Collaborators: Sponsor: Janssen Pharmaceutica N.V., Belgium
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 292
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2001-06
Completion Date: 2005-05
Results First Posted:
Last Update Posted: 2011-02-01
Locations:
URL: https://clinicaltrials.gov/show/NCT00338000